Cart
sales@molnova.com
Tz-Thalidomide
CAS No. 2087490-42-2
Tz-Thalidomide( —— )
Catalog No. M37130 CAS No. 2087490-42-2
Tz-Thalidomide is a tetrazine-modified Thalidomide (E3 ligase ligand) with some affinity for BRD4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 115 | In Stock |
|
| 5MG | 86 | In Stock |
|
| 10MG | 141 | In Stock |
|
| 25MG | 285 | In Stock |
|
| 50MG | 448 | In Stock |
|
| 100MG | 703 | In Stock |
|
| 200MG | 939 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTz-Thalidomide
-
NoteResearch use only, not for human use.
-
Brief DescriptionTz-Thalidomide is a tetrazine-modified Thalidomide (E3 ligase ligand) with some affinity for BRD4.
-
DescriptionTz-Thalidomide is a tetrazine tagged Thalidomide (HY-14658) (Ligands for E3 Ligase). Tz-Thalidomide has binding affinity for BRD4, with IC50s of 46.25 μM (BRD4-1) and 62.55 μM (BRD4-2). Tz-Thalidomide is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2087490-42-2
-
Formula Weight571.58
-
Molecular FormulaC29H29N7O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (87.48 mM; Ultrasonic )
-
SMILESO=C1NC(=O)C(N2C(=O)C=3C=CC=C(OCCCCCC(=O)NCC=4C=CC(=CC4)C5=NN=C(N=N5)C)C3C2=O)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lebraud H, et al. Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras. ACS Cent Sci. 2016 Dec 28;2(12):927-934.?
molnova catalog
related products
-
ZEN-3694
ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
-
GSK8573
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
BRD4?Inhibitor-27
BRD4?Inhibitor-27 is a potent BRD4 inhibitor that inhibits BRD4 BD1 and BRD4 BD2 with IC50s of 9.6 and 11.3 μM, respectively.BRD4?Inhibitor-27 has anticancer activity and can be used for breast cancer research.
